CMS Offers New Details on Patient Registry for Alzheimer’s Drugs

CMS is releasing updates on how people can get drugs that might slow the progression of Alzheimer’s covered by Medicare, according to the Center for Medicare & Medicaid Services Thursday.

Specifically, the agency offered new details on how its registry will work for patients using the drugs and their providers.

Medicare will cover medicines with traditional FDA approval as long as a physician and clinical team participates in the collection of evidence about how these drugs work.

Clinicians will submit information through a CMS-facilitated portal, or registry, and researchers and CMS will maintain access to the registry to conduct ...